Tom Coll

Partner
collta@cooley.com
Full contact info

I represent public and private emerging companies, including leading life sciences companies, on general corporate and transactional matters. I assist clients with corporate, governance, securities, licensing and contractual matters, as well as capital markets and M&A transactional matters. I often work with emerging companies from inception through IPO and beyond. I also work with a number of leading venture capital firms on their investment transactions.

About Tom

Tom Coll's practice covers a broad range of general corporate matters, including counseling public and privately held companies regarding disclosure and reporting requirements, technology licensing, equity incentives, employee compensation and benefits and the formation of new businesses. Tom also represents clients in a broad range of transactional matters, including public offerings, public and private company mergers and acquisitions, corporate partnering and licensing transactions, spin-offs and venture capital financings. He is counsel to public and private companies in a broad range of industries, including biotechnology, medical devices, information storage and wireless communications.

View full bio

Experience

Tentarix Biotherapeutics Announces Three Collaborations, Plus Acquisition Options With Gilead Sciences

Tentarix Biotherapeutics Announces Three Collaborations, Plus Acquisition Options With Gilead Sciences

August 15, 2023

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.

Read more

Related contacts

Charity Williams
Partner, San Diego
Rama Padmanabhan
Partner, San Diego
Ritu Gupta
Special Counsel, New York
Jameson Davis
Associate, Boston
Lindsey O'Crump
Associate, Washington, DC
Joshua C. Allen
Associate, Chicago
Todd Gluth
Partner, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Howard Morse
Partner, Washington, DC
Rubin Waranch
Associate, Colorado
Lei Shen
Partner, Chicago
Gary Warren Hunt III
Associate, Washington, DC
Kristin R. Marshall
Associate, Washington, DC
Ross Eberly
Partner, Santa Monica
Tom Coll
Partner, San Diego
Edmond Lay
Associate, San Diego
Max Levinbook
Associate, San Diego
Barbara Mirza
Partner, Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC

Related Practices & Industries

Life Sciences
Life Sciences Corporate Partnering and Licensing
Mergers and Acquisitions
Tax
Antitrust and Competition
Cyber/Data/Privacy
Labor and Employment
Compensation and Benefits
Healthcare

Morphimmune Announces Merger With Immunome and $125 Million Private Investment

Morphimmune Announces Merger With Immunome and $125 Million Private Investment

July 5, 2023

Cooley advised Morphimmune, a private biotechnology company, in its definitive merger agreement with Immunome and $125 million private investment.

Read more

Related contacts

Tom Coll
Partner, San Diego
Barbara Borden
Partner, San Diego
Carlos Ramirez
Partner, San Diego
Dylan Kornbluth
Associate, San Diego
Polina A. Demina
Special Counsel, New York
Kyrsten Lundh
Associate, San Diego
Daniel Gillon
Associate, San Diego
Nyron J. Persaud
Partner, New York
Todd Gluth
Partner, San Diego
Ross Eberly
Partner, Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
Ajay Athavale
Associate, San Francisco
Nathaniel Hearn Jr.
Associate, Chicago
Terren O'Connor
Associate, San Diego
Eileen Leman
Associate, Los Angeles

Related Practices & Industries

Mergers and Acquisitions
Life Sciences
Emerging Companies
Compensation and Benefits
Labor and Employment
Tax
Antitrust and Competition

Red Tree Venture Capital – $108 Million Oversubscribed Series B Financing

Red Tree Venture Capital – $108 Million Oversubscribed Series B Financing

March 6, 2023

Cooley advised Red Tree Venture Capital on a $108 million oversubscribed Series B financing – co-led by RA Capital Management – in Bicara Therapeutics, a clinical-stage biotechnology company developing biologics for anti-tumor response.

Related contacts

Terren O'Connor
Associate, San Diego
Michelle Hunt
Associate
Tom Coll
Partner, San Diego

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences
Biotechnology

Wugen Closes Oversubscribed $172 Million Series B Financing

Wugen Closes Oversubscribed $172 Million Series B Financing

December 12, 2022

Cooley represented Wugen, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies, on its oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Partner Tom Coll led the Cooley team.

Related contacts

Heidi E. Wang
Associate, San Diego
Edmond Lay
Associate, San Diego
Tom Coll
Partner, San Diego

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences

Genomatica Closes $118 Million Series C Financing

Genomatica Closes $118 Million Series C Financing

December 12, 2022

Cooley represented Genomatica, a sustainability leader in the commercialization and expansion of sustainable materials, in its $118 million Series C funding led by Novo Holdings. Partner Tom Coll led the Cooley team.

Related contacts

Edmond Lay
Associate, San Diego
Tom Coll
Partner, San Diego
Sarah Oliai
Associate, Washington, DC

Related Practices & Industries

Emerging Companies
Venture Capital
Cleantech
Government Contracts
View more

Admissions and credentials

California

Rankings and accolades

Chambers USA: Band 1 for Corporate/M&A – California: San Diego (2020 – 2023)

Best Lawyers in America: Biotechnology Law and Life Sciences, Corporate Law, Leveraged Buyouts and Private Equity Law and Venture Capital Law

Best Lawyers in America: Lawyer of the Year - Leveraged Buyouts and Private Equity Law (2021)

Southern California Super Lawyers: Business/Corporate Law (2007-2014, 2018-2019)

Memberships and affiliations

American Bar Association (ABA)

San Diego County Bar Association